Clinical trial · Interventional
Combination of Ibrutinib and As2O3 in the Treatment of CLL
NCT02757040CI-TRIAL-00021965unknownPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether the combination of As2O3 and ibrutinib is synergistic in chronic lymphocytic leukemia
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ibrutinib | Drug | Ibrutinib | ALIAS |
| Ibrutinib combined with As2O3 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Ibrutinib combined with As2O3
- description
- Ibrutinib combined with As2O3
- interventionNames
- Drug: Ibrutinib combined with As2O3
- type
- ACTIVE_COMPARATOR
- label
- Ibrutinib
- description
- Ibrutinib only
- interventionNames
- Drug: ibrutinib
Primary outcomes (1)
- measure
- overall response rate
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * patients fulfilling clinical and immune-phenotypic criteria for CLL Exclusion Criteria: * none
References
Publications (0)
Data not yet available
No reference posted for this study.